IDH1 and central nervous system cancer: Our results clearly indicate a potential for successful transfer of our method towards IDH1 wildtype glioma; however, validation is limited due to the current lack of specific histopathological tumor-cell markers that can be combined with other markers in multiplexed immunhohistochemistry.